SEARCH

SEARCH BY CITATION

References

  • 1
    Sutherland LR, May GR, Shaffer EA. Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann Intern Med 1993; 118: 5409.
  • 2
    Kornbluth AA, Salomon P, Sacks HS, Mitty R, Janowitz HD. Metaanalysis of the effectiveness of current drug therapy of ulcerative colitis. J Clin Gastroenterol 1993; 16: 2158.
  • 3
    Lichtiger S, Present DH, Kornbluth A, et al. Ciclosporin in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330: 18415.
  • 4
    Leijonmarck CE, Persson PG, Hellers G. Factors affecting colectomy rate in ulcerative colitis: an epidemiologic study. Gut 1990; 31: 32933.
  • 5
    Feshner PR, Michelassi F, Rubin M, Hanauer SB, Plevy SE, Targan SR. Morbidity of subtotal colectomy in patients with severe ulcerative colitis unresponsive to cyclosporin. Dis Colon Rectum 1995; 38: 12415.
  • 6
    Andus T, Gross V. Etiology and pathophysiology of inflammatory bowel disease – environmental factors. Hepatogastroenterology 2000; 47: 2943.
  • 7
    Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998; 115: 182205.
  • 8
    Ghosh S, Shand A, Ferguson A. Ulcerative colitis. Br Med J 2000; 320: 111923.
  • 9
    Mansfield JC, Holden H, Tarlow JK, et al. Novel genetic association between ulcerative colitis and the antiinflammatory cytokine interleukin-1 receptor antagonist. Gastroenterology 1994; 106: 63742.
  • 10
    Andus T, Daig R, Vogl D, et al. Imbalance of the interleukin 1 system in colonic mucosa—association with intestinal inflammation and interleukin-1 receptor antagonist genotype 2. Gut 1997; 41: 6517.
  • 11
    Targan SR, Hanauer SB, Van Deventer SJ, et al. A short-term study of chronic monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 102935.
  • 12
    Evans RC, Clarke L, Heath P, Stephens S, Moris AI, Rhodes JM. Treatment of ulcerative colitis with an engineered human anti-TNFα antibody CHP571. Aliment Pharmacol Ther 1997; 11: 10315.
  • 13
    Vantrappen G, Coremanns G, Biliau A, De Somer P. Treatment of Crohn's disease with interferon. A preliminary clinical trial. Acta Clinica Belgica 1980; 35: 23842.
  • 14
    Hazisemilovic P, Emmons L, Schaub U. Interferon-α2a (Roferon) treatment of inflammatory bowel disease in children and adolescents. Inflammatory bowel disease and morbus Hirschsprung. Falk Symposium on Pediatric and Surgical Gastroenterology, 2nd, Basel, Switzerland, 1992: 10923.
  • 15
    Davidsen B, Munkholm P, Schlichting P, Nielsen OH, Krarup H, Bonnevie-Nielsen V. Tolerability of interferon-α2b, a possible new treatment of active Crohn's disease. Aliment Pharmacol Ther 1995; 91: 759.
  • 16
    Wirth H, Zala G, Meyenberger C, Jost R, Ammann R, Munch R. Alpha-Interferon therapy in Crohn's disease: Initial clinical results. Schweiz Med Wochenschrift 1993; 123: 13848.
  • 17
    Hanauer S, Baert F, Robinson M. Interferon treatment in mild to moderate active Crohn's disease: Preliminary results of an open label pilot study. Gastroenterology 1994; 106: A696A696(Abstract).
  • 18
    Gasche C, Reinisch W, Vogelsang H, et al. Prospective evaluation of interferon α in treatment of chronic active Crohn's disease. Dig Dis Sci 1995; 40: 8004.
  • 19
    Boerr L, Sambuelli A, Gil A. Alpha-interferon was not effective treatment of patients with ulcerative colitis. Gastroenterology 1996; 1104: A868A868(Abstract).
  • 20
    Sümer N, Palabiyikoglu M. Induction of remission by interferon-a in patients with chronic active ulcerative colitis. Eur J Gastroent Hepatol 1995; 7: 597602.
  • 21
    Noscworthy JH, Luchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000; 343: 93852.
  • 22
    Arnason BG, Dayal A, Qu ZX, Jensen MA, Genc K, Reder AT. Mechanisms of action of interferon-β in multiple sclerosis. Springer Semin Immun Pathol 1996; 18: 12548.
  • 23
    Arnason BG. Interferon β in multiple sclerosis. Clin Immunol Immunopathol 1996; 81: 111.DOI: 10.1006/clin.1996.0149
  • 24
    Rudick RP, Ransohoff RM, Pepper R, Mendendorp SV, Lehnmann P, Alarm J. Interferon β induces interleukin 10 expression: relevance to multiple sclerosis. Ann Neurol 1996; 40: 61827.
  • 25
    Sciacca FL, Canal N, Edoardo Grimaldi LM. Induction of IL-1 receptor antagonist by interferon β: implication for the treatment of multiple sclerosis. J Neurovirol 2000; 6(Suppl. 2): S337.
  • 26
    Liu Z, Pelfrey CM, Cotleur A, Lee J, Rudick RA. Immunmodulatory effects of interferon-β-1a in multiple sclerosis. J Neuroimmunol 2001; 112: 15362.
  • 27
    Hoffmann T, Lizzio EF, Ting A, Marshall LA, Bonvini E, Jennings MK. Release of arachidonic acid metabolite by human monocytes or lymphocytes: effect of treatment with interferon on stimulation by phorbol ester or calicium ionophore. Clin Immunol Immunopathol 1987; 44: 8292.
  • 28
    Ito M, Ishida E, Tnabe F, Shigeta S, Watanabe Y, Kawade Y. Interferon-a enhances the prodution of leukotriene B4 in murine peritoneal macrophages stimulated by opsonized zymosan. Immunology 1987; 60: 6179.
  • 29
    Rachmilewitz D on behalf of an International Study Group. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. Br Med J 1989; 298: 826.
  • 30
    Ilnyckyi A, Shanahan F, Anton PA, Cheang M, Bernstein CN. Quantification of the placebo response in ulcerative colitis. Gastroenterology 1997; 112: 18548.
  • 31
    Brynskov J. Cyclosporin for the inflammatory bowel disease: Mechanisms and possible actions. Scand J Gastroenterol 1993; 28: 84957.
  • 32
    Sümer N, Palabiyikoglu M. Induction of remission by interferon-α in patients with chronic active ulcerative colitis. Eur J Gastroenterol Hepatol 1995; 7: 597602.
  • 33
    Rüther U, Nunnensiek C, Muller HA, Bader H, May U, Jipp P. Interferon alpha (IFN α2a) therapy for herpes virus-associated inflammatory bowel disease (ulcerative colitis and Crohn's disease). Hepatogastroenterology 1998; 45(21): 6919.